Caplin Point Laboratories Limited (BOM:524742)
1,887.90
-2.25 (-0.12%)
At close: Apr 23, 2025
Caplin Point Laboratories Revenue
Caplin Point Laboratories had revenue of 4.93B INR in the quarter ending December 31, 2024, with 13.19% growth. This brings the company's revenue in the last twelve months to 18.90B, up 15.84% year-over-year. In the fiscal year ending March 31, 2024, Caplin Point Laboratories had annual revenue of 16.96B with 15.51% growth.
Revenue (ttm)
18.90B
Revenue Growth
+15.84%
P/S Ratio
7.58
Revenue / Employee
5.55M
Employees
3,406
Market Cap
143.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
Mar 31, 2021 | 10.62B | 1.98B | 22.96% |
Mar 31, 2020 | 8.64B | 2.15B | 33.12% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,409.52B |
Infosys | 1,647.16B |
Bajaj Finance | 358.05B |
Caplin Point Laboratories News
- 1 day ago - Caplin Point subsidiary Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion - Business Upturn
- 21 days ago - Caplin Point Laboratories shares jump over 3% after acquiring Neoethicals Chile SpA - Business Upturn
- 2 months ago - Caplin Point subsidiary secures USFDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution - Business Upturn
- 2 months ago - Caplin Point Laboratories Q3 FY25 Results: Revenue up 13% YoY to Rs 493 crore, Net Profit up 17% YoY - Business Upturn
- 2 months ago - Caplin Point Laboratories subsidiary secures USFDA approval for Procainamide Hydrochloride Injection - Business Upturn
- 3 months ago - Caplin Point Laboratories subsidiary gets USFDA nod for Levetiracetam in sodium chloride injection - Business Upturn
- 3 months ago - Caplin Point receives zero 483 observation from USFDA in recent inspection - Business Upturn
- 4 months ago - Stock Market Update, December 27: Oberoi Realty, Caplin Point Laboratories and Jubilant FoodWorks hit 52-week highs today - Business Upturn